Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen Financing Round, Led by Sprout Group, Raises $11M


SAN CARLOS, Calif.--Deltagen, a biotechnology company specializing in gene function determination, announced the completion of a second round of financing that netted $11.5 million.

The round was led by Sprout Group, Menlo Park, Calif., and included investments by Baccharis Capital, also in Menlo Park, and Tularik, in South San Francisco, Calif.

Deltagen has developed an integrated genomics approach that moves from identifying novel genes to determining their in vivo biological function. Analyses are derived using the company's proprietary mouse gene knockout technology, which enhances both the speed and the throughput of targeted gene knockouts in mice and allows for the assessment of hundreds of genes per year, Deltagen claimed.

Founded in 1997, Deltagen has raised a total of $14.5 million in equity investments. The company currently has over 250 gene knockout programs in its internal research pipeline and plans to expand research to new technologies and corporate partners over the next several months.

Deltagen's initial strategy focuses on employing its biological systems expertise and bioinformatics capabilities to determine novel gene function in the areas of immune response, inflammation, hematopoiesis, and angiogenesis, and in the development and maintenance of the central nervous system.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.